These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23765241)

  • 1. Duck HBV DNA copy numbers in isolated hepatocyte nuclei vary dramatically and decline during entecavir therapy.
    Shen G; Fu X; Zhou B; Yin J; Zhong C; Chen J; Hou J
    Antivir Ther; 2013; 18(8):987-96. PubMed ID: 23765241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
    Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
    Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
    J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
    Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
    Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
    Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
    Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
    Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
    J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.
    Marion PL; Salazar FH; Winters MA; Colonno RJ
    Antimicrob Agents Chemother; 2002 Jan; 46(1):82-8. PubMed ID: 11751115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
    Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
    J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
    Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
    Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
    Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of a universal Taqman real-time PCR for quantitation of duck hepatitis B virus DNA.
    Wang Y; Li Y; Yang C; Hui L; Han Q; Ma L; Wang Q; Yang G; Liu Z
    J Virol Methods; 2013 Jul; 191(1):41-7. PubMed ID: 23557670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the replication of hepatitis B virus compared with that of duck hepatitis B virus in primary duck hepatocytes].
    Yao Y; Tang N; Huang A
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1157-61. PubMed ID: 11769700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
    Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
    Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
    Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
    Schorr O; Borel C; Trepo C; Zoulim F; Hantz O
    J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
    Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
    Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2',3'-dideoxy-3'-fluoroguanosine inhibits duck hepatitis B virus in vivo.
    Löfgren B; Vickery K; Zhang YY; Nordenfelt E
    J Viral Hepat; 1996 Mar; 3(2):61-5. PubMed ID: 8811639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
    Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
    J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.